Department of Veterinary Surgery and Animal Reproduction, School of Veterinary Medicine and Animal Science, São Paulo State University-UNESP, Botucatu 18618-681, Brazil.
Department of Veterinary Clinic, School of Veterinary Medicine and Animal Science, São Paulo State University-UNESP, Botucatu 18618-681, Brazil.
Molecules. 2021 Feb 25;26(5):1213. doi: 10.3390/molecules26051213.
Rapamycin is an antifungal drug with antitumor activity and acts inhibiting the mTOR complex. Due to drug antitumor potential, the aim of this study was to evaluate its effect on a preclinical model of primary mammary gland tumors and their metastases from female dogs. Four cell lines from our cell bank, two from primary canine mammary tumors (UNESP-CM1, UNESP-CM60) and two metastases (UNESP-MM1, and UNESP-MM4) were cultured in vitro and investigated for rapamycin IC. Then, cell lines were treated with rapamycin IC dose and mRNA and protein were extracted in treated and non-treated cells to perform AKT, mTOR, PTEN and 4EBP1 gene expression and global proteomics by mass spectrometry. MTT assay demonstrated rapamycin IC dose for all different tumor cells between 2 and 10 μM. RT-qPCR from cultured cells, control versus treated group and primary tumor cells versus metastatic tumor cells, did not shown statistical differences. In proteomics were found 273 proteins in all groups, and after data normalization 49 and 92 proteins were used for statistical analysis for comparisons between control versus rapamycin treatment groups, and metastasis versus primary tumor versus metastasis rapamycin versus primary tumor rapamycin, respectively. Considering the two statistical analysis, four proteins, phosphoglycerate mutase, malate dehydrogenase, l-lactate dehydrogenase and nucleolin were found in decreased abundance in the rapamycin group and they are related with cellular metabolic processes and enhanced tumor malignant behavior. Two proteins, dihydrolipoamide dehydrogenase and superoxide dismutase, also related with metabolic processes, were found in higher abundance in rapamycin group and are associated with apoptosis. The results suggested that rapamycin was able to inhibit cell growth of mammary gland tumor and metastatic tumors cells in vitro, however, concentrations needed to reach the IC were higher when compared to other studies.
雷帕霉素是一种具有抗肿瘤活性的抗真菌药物,作用于 mTOR 复合物。由于该药物具有抗肿瘤潜力,本研究旨在评估其对雌性犬原发性乳腺肿瘤及其转移的临床前模型的影响。我们的细胞库中的四种细胞系,两种来自原发性犬乳腺肿瘤(UNESP-CM1、UNESP-CM60)和两种转移瘤(UNESP-MM1 和 UNESP-MM4)在体外进行培养,并检测雷帕霉素的 IC50。然后,用雷帕霉素 IC50 剂量处理细胞系,并提取处理和未处理细胞中的 mRNA 和蛋白质,通过质谱法进行 AKT、mTOR、PTEN 和 4EBP1 基因表达和全局蛋白质组学分析。MTT 试验表明,所有不同肿瘤细胞的雷帕霉素 IC50 剂量在 2 至 10 μM 之间。来自培养细胞的 RT-qPCR 显示,对照组与处理组、原发性肿瘤细胞与转移性肿瘤细胞之间均无统计学差异。在蛋白质组学中,所有组中共发现 273 种蛋白质,经过数据归一化后,分别用于对照组与雷帕霉素处理组、转移瘤与原发性肿瘤、转移性肿瘤与原发性肿瘤-雷帕霉素之间的统计学分析的有 49 种和 92 种蛋白质。考虑到这两种统计分析,在雷帕霉素组中发现了 4 种蛋白质(磷酸甘油酸变位酶、苹果酸脱氢酶、L-乳酸脱氢酶和核仁素)的丰度降低,它们与细胞代谢过程和增强肿瘤恶性行为有关。两种与代谢过程有关的蛋白质,即二氢硫辛酰胺脱氢酶和超氧化物歧化酶,在雷帕霉素组中丰度增加,与细胞凋亡有关。结果表明,雷帕霉素能够抑制体外乳腺肿瘤和转移瘤细胞的生长,但与其他研究相比,达到 IC50 所需的浓度更高。